Literature DB >> 21242515

IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression.

Andrew Johnston1, Xianying Xing, Andrew M Guzman, MaryBeth Riblett, Candace M Loyd, Nicole L Ward, Christian Wohn, Errol P Prens, Frank Wang, Lisa E Maier, Sewon Kang, John J Voorhees, James T Elder, Johann E Gudjonsson.   

Abstract

IL-1F6, IL-1F8, and IL-1F9 and the IL-1R6(RP2) receptor antagonist IL-1F5 constitute a novel IL-1 signaling system that is poorly characterized in skin. To further characterize these cytokines in healthy and inflamed skin, we studied their expression in healthy control, uninvolved psoriasis, and psoriasis plaque skin using quantitative RT-PCR and immunohistochemistry. Expression of IL-1F5, -1F6, -1F8, and -1F9 were increased 2 to 3 orders of magnitude in psoriasis plaque versus uninvolved psoriasis skin, which was supported immunohistologically. Moreover, treatment of psoriasis with etanercept led to significantly decreased IL-1F5, -1F6, -1F8, and -1F9 mRNAs, concomitant with clinical improvement. Similarly increased expression of IL-1F5, -1F6, -1F8, and -1F9 was seen in the involved skin of two mouse models of psoriasis. Suggestive of their importance in inflamed epithelia, IL-1α and TNF-α induced IL-1F5, -1F6, -1F8, and -1F9 transcript expression by normal human keratinocytes. Microarray analysis revealed that these cytokines induce the expression of antimicrobial peptides and matrix metalloproteinases by reconstituted human epidermis. In particular, IL-1F8 increased mRNA expression of human β-defensin (HBD)-2, HBD-3, and CAMP and protein secretion of HBD-2 and HBD-3. Collectively, our data suggest important roles for these novel cytokines in inflammatory skin diseases and identify these peptides as potential targets for antipsoriatic therapies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21242515      PMCID: PMC3074475          DOI: 10.4049/jimmunol.1003162

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

1.  A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.

Authors:  Angela Moore; Kenneth B Gordon; Sewon Kang; Alice Gottlieb; Bruce Freundlich; H Amy Xia; Seth R Stevens
Journal:  J Am Acad Dermatol       Date:  2006-11-17       Impact factor: 11.527

2.  Cutting edge: opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediated suppression.

Authors:  Ilona Kryczek; Shuang Wei; Linhua Vatan; June Escara-Wilke; Wojciech Szeliga; Evan T Keller; Weiping Zou
Journal:  J Immunol       Date:  2007-08-01       Impact factor: 5.422

3.  Four new members expand the interleukin-1 superfamily.

Authors:  D E Smith; B R Renshaw; R R Ketchem; M Kubin; K E Garka; J E Sims
Journal:  J Biol Chem       Date:  2000-01-14       Impact factor: 5.157

4.  Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta.

Authors:  A Hildebrand; M Romarís; L M Rasmussen; D Heinegård; D R Twardzik; W A Border; E Ruoslahti
Journal:  Biochem J       Date:  1994-09-01       Impact factor: 3.857

5.  Evidence for an alternative pathway of keratinocyte maturation in psoriasis from an antigen found in psoriatic but not normal epidermis.

Authors:  J N Mansbridge; A M Knapp; A M Strefling
Journal:  J Invest Dermatol       Date:  1984-10       Impact factor: 8.551

Review 6.  Transforming growth factor-beta and p-21: multiple molecular targets of decorin-mediated suppression of neoplastic growth.

Authors:  M Ständer; U Naumann; W Wick; M Weller
Journal:  Cell Tissue Res       Date:  1999-05       Impact factor: 5.249

7.  IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL-1Rrp.

Authors:  G Pan; P Risser; W Mao; D T Baldwin; A W Zhong; E Filvaroff; D Yansura; L Lewis; C Eigenbrot; W J Henzel; R Vandlen
Journal:  Cytokine       Date:  2001-01-07       Impact factor: 3.861

8.  TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells.

Authors:  Marc Veldhoen; Richard J Hocking; Christopher J Atkins; Richard M Locksley; Brigitta Stockinger
Journal:  Immunity       Date:  2006-02       Impact factor: 31.745

9.  IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin.

Authors:  Theoharis C Theoharides; Bodi Zhang; Duraisamy Kempuraj; Michael Tagen; Magdalini Vasiadi; Asimenia Angelidou; Konstantinos-Dionysios Alysandratos; Dimitris Kalogeromitros; Shahrzad Asadi; Nikolaos Stavrianeas; Erika Peterson; Susan Leeman; Pio Conti
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

10.  Decreased levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-TNF-alpha.

Authors:  Paola Cordiali-Fei; Elisabetta Trento; Giovanna D'Agosto; Valentina Bordignon; Anna Mussi; Marco Ardigò; Antonio Mastroianni; Antonella Vento; Francesco Solivetti; Enzo Berardesca; Fabrizio Ensoli
Journal:  J Autoimmune Dis       Date:  2006-10-05
View more
  103 in total

1.  IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist.

Authors:  Frank L van de Veerdonk; Angela K Stoeckman; Gouping Wu; Aaron N Boeckermann; Tania Azam; Mihai G Netea; Leo A B Joosten; Jos W M van der Meer; Ruyi Hao; Vassili Kalabokis; Charles A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

2.  DIRA, DITRA, and new insights into pathways of skin inflammation: what's in a name?

Authors:  Edward W Cowen; Raphaela Goldbach-Mansky
Journal:  Arch Dermatol       Date:  2012-03

3.  Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis.

Authors:  Alexandros Onoufriadis; Michael A Simpson; Andrew E Pink; Paola Di Meglio; Catherine H Smith; Venu Pullabhatla; Jo Knight; Sarah L Spain; Frank O Nestle; A David Burden; Francesca Capon; Richard C Trembath; Jonathan N Barker
Journal:  Am J Hum Genet       Date:  2011-08-11       Impact factor: 11.025

4.  The double-stranded RNA analogue polyinosinic-polycytidylic acid induces keratinocyte pyroptosis and release of IL-36γ.

Authors:  Li-Hua Lian; Katelynn A Milora; Katherine K Manupipatpong; Liselotte E Jensen
Journal:  J Invest Dermatol       Date:  2012-02-09       Impact factor: 8.551

5.  Interleukin-36α axis is modulated in patients with primary Sjögren's syndrome.

Authors:  F Ciccia; A Accardo-Palumbo; R Alessandro; C Alessandri; R Priori; G Guggino; S Raimondo; F Carubbi; G Valesini; R Giacomelli; A Rizzo; G Triolo
Journal:  Clin Exp Immunol       Date:  2015-06-03       Impact factor: 4.330

6.  IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis.

Authors:  Andrew Johnston; Xianying Xing; Liza Wolterink; Drew H Barnes; ZhiQiang Yin; Laura Reingold; J Michelle Kahlenberg; Paul W Harms; Johann E Gudjonsson
Journal:  J Allergy Clin Immunol       Date:  2016-12-31       Impact factor: 10.793

7.  Decreased Langerhans cell responses to IL-36γ: altered innate immunity in patients with recurrent respiratory papillomatosis.

Authors:  James DeVoti; Lynda Hatam; Alexandra Lucs; Ali Afzal; Allan Abramson; Bettie Steinberg; Vincent Bonagura
Journal:  Mol Med       Date:  2014-08-28       Impact factor: 6.354

Review 8.  Psoriasis: a mixed autoimmune and autoinflammatory disease.

Authors:  Yun Liang; Mrinal K Sarkar; Lam C Tsoi; Johann E Gudjonsson
Journal:  Curr Opin Immunol       Date:  2017-07-22       Impact factor: 7.486

9.  Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk.

Authors:  Luigi Tortola; Esther Rosenwald; Brian Abel; Hal Blumberg; Matthias Schäfer; Anthony J Coyle; Jean-Christoph Renauld; Sabine Werner; Jan Kisielow; Manfred Kopf
Journal:  J Clin Invest       Date:  2012-10-15       Impact factor: 14.808

10.  IL-36γ/IL-1F9, an innate T-bet target in myeloid cells.

Authors:  Malte Bachmann; Patrick Scheiermann; Lorena Härdle; Josef Pfeilschifter; Heiko Mühl
Journal:  J Biol Chem       Date:  2012-10-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.